Abstract 1580
Background
Brain metastases (BMs) account for a relatively large proportion of patients with metastatic non-small cell lung cancer (NSCLC) both at the time of diagnosis and during the course of disease, which is a major cause leading to a significant increase in cancer-related mortality for NSCLC patients. We aimed to build a novel risk classification system to predict overall survival (OS) of patients presenting with BMs at the first diagnosis of NSCLC.
Methods
Data on NSCLC patients with BMs was extracted from the SEER database between 2010 and 2013. All cases were randomly divided into the training cohort and validation cohort (7:3). Cox regression was performed to select the independent predictors of OS. A nomogram was established for predicting 6-, 12- and 18-month OS. The prognostic performance of nomogram was evaluated using concordance indexes (C-indexes), calibration curves, and decision curve analyses (DCAs). All statistical analysis was performed with R software.
Results
According to the multivariate Cox regression of the training set, the following variables were contained in the nomogram prognostic model: age, marital status, sex, race, primary site, histological type, T stage, N stage, metastatic pattern, whether received radiotherapy and chemotherapy. The nomogram displayed good accuracy in predicting 6, 12 and 18 months OS. The C-indexes of training set and validation set were 0.729 and 0.723, respectively. The calibration curves showed excellent consistency between the actual results and the nomogram prediction, and the DCAs exhibited great clinical utility of the model. A new risk classification system based on nomogram scores was introduced to classify NSCLC patients with BMs into three subgroups. In the training cohort, the median OS of patients in the low-, intermediate- and high-risk groups was 11.0 months (95% confidence interval [CI] 10.3–11.7), 5.0 months (95% CI 4.6–5.4), and 2.0 months (95% CI 1.9–2.1), respectively.
Conclusions
We established a risk stratification system based on nomogram scores to predict the OS of patients presenting with BMs at initial diagnosis of NSCLC. These predictive models can act as auxiliary tools to guide treatment strategies and prognostic evaluation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2023 - Patients with brain metastases treated with afatinib in clinical practice – results from the prospective non-interventional study GIDEON
Presenter: Eckart Laack
Session: Poster Display session 1
Resources:
Abstract
1613 - Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: initial Phase 1b results
Presenter: David Berz
Session: Poster Display session 1
Resources:
Abstract
2853 - Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC
Presenter: Petros Christopoulos
Session: Poster Display session 1
Resources:
Abstract
1974 - A Phase II Open-Label, Multicentre Study to Assess the Anti-tumour Activity of Afatinib in Patients with Activating Epidermal Growth Factor Receptor mutation (EGFRm) from Circulating Tumor DNA (CtDNA)
Presenter: Young-Chul Kim
Session: Poster Display session 1
Resources:
Abstract
3370 - Influence of cow’s milk on the absorption and exposure of erlotinib in NSCLC patients
Presenter: Geerten Veerman
Session: Poster Display session 1
Resources:
Abstract
5900 - PTEN loss as Predictor of Tumor Heterogeneity (TH) and Poor Prognosis in EGFR-mutant Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients (pts) Receiving Tyrosine-Kinase Inhibitors (TKIs).
Presenter: Miriam Ferrara
Session: Poster Display session 1
Resources:
Abstract
1302 - Safety of lorlatinib in subgroups of patients from a phase 1/2 trial
Presenter: Enriqueta Felip
Session: Poster Display session 1
Resources:
Abstract
1497 - Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase 2 ALTA trial
Presenter: Dae Ho Lee
Session: Poster Display session 1
Resources:
Abstract
2349 - The safety assessment of crizotinib and alectinib from real world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L).
Presenter: Kei Kunimasa
Session: Poster Display session 1
Resources:
Abstract
1120 - Brigatinib in ALK TKI-pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC): the Use Via Expanded Access to Brigatinib (UVEA-Brig) study
Presenter: Silvia Novello
Session: Poster Display session 1
Resources:
Abstract